Working… Menu

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02595866
Recruitment Status : Recruiting
First Posted : November 4, 2015
Last Update Posted : December 3, 2021
Information provided by (Responsible Party):
National Cancer Institute (NCI)